RNN Key Statistics, Chart & Performance
The current stock price of RNN is 5.24 null. In the past month the price decreased by -10.27%. In the past year, price decreased by -76.52%.
About RNN
Company Profile
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
Company Info
REXAHN PHARMACEUTICALS INC
15245 SHADY GROVE ROAD SUITE 455
ROCKVILLE MD 20850
CEO: Douglas J. Swirsky
Phone: 240-268-5300
REXAHN PHARMACEUTICALS INC / RNN FAQ
What does REXAHN PHARMACEUTICALS INC do?
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
Can you provide the latest stock price for REXAHN PHARMACEUTICALS INC?
The current stock price of RNN is 5.24 null. The price increased by 0.19% in the last trading session.
What is the dividend status of REXAHN PHARMACEUTICALS INC?
RNN does not pay a dividend.
What is the ChartMill technical and fundamental rating of RNN stock?
RNN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is REXAHN PHARMACEUTICALS INC worth?
REXAHN PHARMACEUTICALS INC (RNN) has a market capitalization of 21.06M null. This makes RNN a Nano Cap stock.
RNN Technical Analysis
RNN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNN. While RNN seems to be doing ok healthwise, there are quite some concerns on its profitability.
RNN Financial Highlights
Over the last trailing twelve months RNN reported a non-GAAP Earnings per Share(EPS) of -3.53. The EPS decreased by -498.31% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -75.35% | ||
| ROE | -91.82% | ||
| Debt/Equity | 0.01 |